An FDA Pharmacy Compounding Advisory Committee narrowly recommended loosening restrictions to allow compounding pharmacies to produce several popular peptides, including BPC-157 and KPV. The move was part of a broader push supported by Health Secretary Robert F. Kennedy Jr., but FDA career scientists warned there is insufficient evidence on safety and effectiveness. The committee’s votes were close (for example 8-6 on BPC-157) and the recommendation is non-binding; the final decision remains with the FDA. Critics, including scientists and some panel members with industry ties, warned that many peptides lack robust clinical data and are marketed by influencers and celebrities. Kennedy’s backing and panel connections have raised concerns about conflicts of interest and the policy direction toward expanding access to unproven therapies. Coverage across outlets highlighted the tension between patient access and rigorous safety evaluation as the agency weighs including these compounds on the list for compounding pharmacies.